中信证券发布研报称，脑机接口行业生态正在快速演进，商业化路径日益清晰。脑机接口技术发展可以 恢复身体功能、提升认知能力，实现人与机器协同工作，最后从长远来看，脑机接口技术将推动人类与 机器的共同进化，这不仅将改变我们的生活方式，还将带来新的社会和经济结构。建议关注：1)医疗级 产品快速落地的领先企业；2)消费级产品培育能力优秀的创新公司；3)具有脑机接口关键技术积累的公 司。 中信证券主要观点如下： 脑机接口生态持续演进，商业化落地迎来曙光 脑机接口是一种接连接大脑与外部设备的技术，其核心技术在于解析大脑复杂神经活动中蕴含的信息， 突破传统神经肌肉传导路径的限制，实现大脑与设备之间的双向通信与控制。(半)侵入式脑机接口在疾 病诊疗市场大有可为，非侵入式是消费市场的主流选择。根据Precedence Research研究数据，全球BCI 市场规模有望从2023年的23.5亿美元成长至2033年的108.9亿美元，对应CAGR为16.6%;根据《脑机接口 技术发展与应用研究报告(2023年)》(中国信通院)，医疗是主要产业化方向，占比56%，工业、军事、 娱乐等其他场景占比44%，商业化空间广阔。 严肃医疗领域研 ...

知情人士透露，Merge Labs正在进行新一轮融资，而新资金的主要来源将由OpenAI的风投提供。值得 注意的是，奥特曼将以联合创始人身份参与该项目，与现任World眼球扫描数字身份项目负责人亚历克 斯 布拉尼亚（Alex Blania）共同推动项目启动，但不直接负责Merge Labs的日常运营管理。 据媒体报道，OpenAI及其首席执行官山姆·奥特曼将支持一家新脑机接口公司Merge Labs，与马斯克的 Neuralink展开竞争。 ...

Core Viewpoint - Neuralink, a company representing the future of human-machine symbiosis, may face a strong challenger in Merge Labs, which aims to connect the human brain with computers, similar to Neuralink's goals [1][10]. Group 1: Investment and Competition - OpenAI, led by co-founder Sam Altman, is reportedly preparing to invest in Merge Labs, which is currently raising funds at a valuation of $850 million, with most of the new funding expected to come from OpenAI's venture capital team [5][10]. - Altman is encouraging this investment and will co-found Merge Labs, although he will not be involved in the day-to-day operations of the new project [5][10]. - Merge Labs plans to raise $250 million from OpenAI and other investors, with negotiations still in early stages [10]. Group 2: Neuralink's Position - Neuralink, founded by Elon Musk in 2016, is currently the leader in the brain-computer interface field and recently secured $650 million in funding, reaching a valuation of $9 billion [11][12]. - The company has successfully completed its 8th and 9th brain-computer interface surgeries, gaining significant attention for enabling high-level paraplegics to control devices [12]. Group 3: Broader Context and Developments - The field of brain-computer interfaces has seen a rise in young startups in Silicon Valley, indicating growing interest and competition in this technology [6]. - Altman has previously expressed optimism about the potential for high-bandwidth brain-computer interfaces to emerge soon, possibly as early as 2025 [7][9]. - In addition to Merge Labs, Altman is involved in other cutting-edge projects, including investments in nuclear fission and fusion initiatives [13].

Sam Altman, OpenAI will reportedly back a startup that takes on Musk’s Neuralink | TechCrunch https://t.co/Jy4KpfyTgO ...

Investment Rating - The report indicates a positive outlook for the brain-computer interface (BCI) industry, highlighting significant technological advancements and supportive policies that are expected to drive commercialization [3][5]. Core Insights - The brain-computer interface industry is experiencing a surge in global research and development, particularly driven by companies like Neuralink, which has completed its first human implant surgery, igniting interest in BCI technologies [4][5]. - Domestic companies in China are rapidly advancing their BCI capabilities, with notable clinical trials and successful implementations, suggesting a promising future for commercialization [5][7]. - The report emphasizes the dual resonance of technological progress and policy support, which is paving the way for the BCI industry to enter a phase of rapid development and potential widespread application [7][49]. Summary by Sections 1. Brain-Computer Interface: A Bridge for Communication - BCI technology enables direct communication between the brain and external devices, facilitating control of devices through thought [9][24]. 2. Industry Chain and Applications - The BCI industry relies heavily on the semiconductor sector for upstream components, while the primary application is in the medical field [25][26]. - The report notes that the BCI industry is composed of upstream hardware and software, midstream BCI products, and downstream application solutions, with a significant portion of companies focused on medical applications [26][29]. 3. Technological Advancements and Policy Support - Recent breakthroughs in underlying technologies, including microelectronics and neuroscience, have set the stage for the BCI industry to enter a period of application proliferation [7][55]. - Supportive policies from the Chinese government, including pricing guidelines for BCI services, are facilitating the integration of BCI technologies into clinical practice [7][49]. 4. Global Development and Domestic Progress - The report highlights the rapid development of BCI technologies globally, with various companies making significant strides in research and product development [4][50]. - Domestic companies are increasingly investing in BCI research and development, with a variety of applications emerging, indicating a competitive landscape [5][50]. 5. Medical Applications and Market Potential - The medical field is identified as the primary application area for BCI technologies, with potential market sizes estimated to exceed $300 billion as the technology matures [46][49]. - BCI applications are showing promise in treating conditions such as epilepsy, ALS, and spinal cord injuries, with significant improvements in patient quality of life [37][39][46].

Core Insights - The brain-computer interface (BCI) industry is entering a phase of application popularization driven by technological advancements and policy support [1][2][3] Technological Progress - Significant advancements in underlying technologies such as microelectronics, materials science, chips, neuroscience, and algorithms have laid the foundation for breakthroughs in BCI [1] Policy Support - The National Healthcare Security Administration (NHSA) has initiated pricing projects for BCI technologies, paving the way for clinical application and reimbursement starting July 2025 [2] - In January 2025, Beijing and Shanghai released action plans for BCI development, followed by a detailed implementation opinion from multiple government departments in August 2025 [3] Global Development Trends - Neuralink has sparked a global surge in BCI research, with the first surgery completed in January 2024 and seven patients implanted by June 2025 [4] - Other companies like Apple and Synchron are also advancing BCI technologies, with Apple demonstrating thought-controlled iPad technology for ALS patients [4] Domestic Industry Progress - Domestic companies are rapidly advancing BCI research, with significant milestones achieved in clinical trials, including the first clinical implant by Tsinghua University and Xuanwu Hospital in October 2023 [5] - The first complete paraplegic patient regaining the ability to stand and walk was reported in March 2025, showcasing the potential for commercial applications [5]

Group 1 - Neuralink has successfully implanted the first human brain-machine interface device, marking a significant breakthrough in the field [1][2] - The brain-machine interface market is in its early stages globally, with China showing potential for rapid development due to policy support and resource allocation [1][3] - The global brain-machine interface market is projected to reach $3.7 billion by 2027, while China's market could exceed 120 billion yuan by 2040 [3] Group 2 - The brain-machine interface technology involves a complex supply chain, including hardware components like electrodes and BIC chips, as well as software for signal analysis [2][3] - Major companies such as Google, Microsoft, and Huawei are entering the brain-machine interface sector, with numerous startups also emerging [3][6] - Several listed companies, including iFlytek and Hanwang Technology, are actively exploring applications in the smart interaction and medical fields [6]

Core Viewpoint - Beijing Zhirun Medical Technology Co., Ltd. has completed over 300 million RMB in Series A financing, indicating strong market recognition of its technology and commercialization prospects [3] Group 1: Company Overview - Zhirun Medical focuses on developing a next-generation invasive flexible brain-computer interface (BCI) platform, aiming to revolutionize human-machine interaction [4][5] - Since its establishment in 2022, Zhirun Medical has raised nearly 500 million RMB in total funding, reflecting significant investor confidence in its technological direction [3] Group 2: Technology and Innovation - The invasive BCI technology is gaining attention due to its high bandwidth capabilities, which surpass non-invasive and semi-invasive methods in signal acquisition and neural control [5] - Zhirun Medical has chosen the challenging invasive technology route, similar to Elon Musk's Neuralink, based on a deep understanding of BCI technology's essence [5][6] Group 3: Key Technical Developments - The core of invasive BCI development lies in electrode technology, with Zhirun Medical pioneering high-throughput flexible electrodes that have received patent authorization in both China and the U.S. [7] - The company's innovative design addresses electrode displacement issues, significantly reducing inflammation and ensuring long-term signal stability [7][10] Group 4: Strategic Positioning and Future Plans - Zhirun Medical has established a complete closed-loop system from R&D to large-scale production, ensuring full control over clinical-grade products [10] - The company is well-positioned to leverage recent government policies aimed at promoting BCI industry innovation, aligning its strategy with national objectives [10][11] Group 5: Market Potential and Investor Sentiment - Investors express strong confidence in the commercial potential of invasive BCI technology, highlighting Zhirun Medical's unique position in the market and its comprehensive approach to technology development [11][12] - The company is seen as a leading contender in the BCI field, with expectations for its technology to address unmet medical needs and expand into various applications [11][12][12]

Company Overview - Zhiruan Medical has completed over 300 million yuan in Series A financing, led by the Social Security Fund Zhongguancun Independent Innovation Special Fund, Junlian Capital, and IDG Capital, with continued investment from existing shareholders [1] - Since its establishment in 2022, the company has raised nearly 500 million yuan in total funding, which will primarily be used for the development of new technologies and large-scale clinical trials [1] Technology and Innovation - Zhiruan Medical focuses on invasive brain-computer interface (BCI) technology, which involves implanting electrodes directly into the brain to collect high-resolution neural signals and achieve precise neuron modulation [2] - The company has developed high-throughput flexible electrodes that have received patent authorization in both China and the United States, allowing for efficient neural signal collection and reduced immune response [2][3] - A fully implanted high-throughput wireless signal acquisition system has been created, capable of precise collection of neural action potentials from up to 1024 channels, with a significant reduction in power consumption [3] Research and Development - The company has established a high-precision brain data platform with over 20TB of animal neural data and 6TB of human deep brain data, which aids in training neural models and improving decoding performance [3] - Zhiruan Medical has developed a multi-degree-of-freedom implantation robot that allows for micron-level positioning accuracy, enhancing the efficiency and safety of electrode implantation [3] Industry Context - The global BCI industry is entering a rapid growth phase, with companies like Neuralink making progress in human clinical trials [4] - The shift from rigid to flexible electrodes is seen as crucial for improving signal quality and stability, as well as reducing immune response risks, which are key factors for clinical application [4] - Invasive BCI technology is expected to achieve breakthroughs in treating conditions such as spinal cord injuries, ALS, and depression [4]

Core Insights - The article discusses the establishment of a new company focused on General Artificial Intelligence (AGI) led by Dai Jifeng, a professor at Tsinghua University, and Chen Tianqiao, an entrepreneur and philanthropist [2][12] - The MiroMind AI team has launched the MiroMind Open Deep Research (Miro ODR) project, which is a high-performance, fully open-source deep research initiative, achieving a GAIA score of 82.4, surpassing other models like OpenAI's Deep Research and Manus [3][4] Company Overview - MiroMind aims to create a collaborative environment for building AI rather than providing AI directly, emphasizing community involvement in the development process [5][12] - The company has released four sub-projects on platforms like GitHub and Hugging Face, with plans for monthly updates to enhance the deep research model [5][10] Technical Achievements - MiroMind ODR's GAIA score of 82.4 positions it as the strongest open-source deep research model available, outperforming competitors [4][9] - The project includes various components such as MiroFlow, MiroThinker, MiroVerse, and MiroTrain, each contributing to different aspects of deep research and model training [10][12] Research and Development Focus - The MiroMind team is concentrating on three key areas: AI-driven business decision-making, innovative content distribution algorithms, and AI services tailored for aging and youth demographics [12] - The MiroMind-M1 model, based on 7 billion parameters, has shown superior performance in mathematical reasoning tasks compared to other models [9][11] Leadership and Background - Dai Jifeng has a strong academic and professional background in AI and computer vision, having published over 80 papers and received more than 60,000 citations [7][8] - Chen Tianqiao has a history of investing in brain-computer interface technologies and aims to support long-term, stable investments in hard tech innovations [15][17]